Dose-related reduction in allergen-specific T cells associates with clinical response of atopic dermatitis to methotrexate [9]

British Journal of Dermatology

Volumn 156, Issue 6, 2007, Pages 1376-

  Bateman, E A L ^a   Ardern Jones, M ^a,b   Ogg, G S ^a,b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b CHURCHILL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; METHOTREXATE;

APOPTOSIS; ATOPIC DERMATITIS; CASE REPORT; CD4+ T LYMPHOCYTE; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFECT; HUMAN; LETTER; LONGITUDINAL STUDY; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 34447101744     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2007.07879.x     Document Type: Letter

References (10)

1. Shaffrali FC, Colver GB, Messenger AG, Gawkrodger DJ. Experience with low-dose methotrexate for the treatment of eczema in the elderly. J Am Acad Dermatol 2003 48: 417 19.
2. Balasubramaniam P, Ilchyshyn A. Successful treatment of severe atopic dermatitis with methotrexate. Clin Exp Dermatol 2005 30: 436 7.
3. Goujon C, Berard F, Dahel K et al. Methotrexate for the treatment of adult atopic dermatitis. Eur J Dermatol 2006 16: 155 8.
4. Haselden BM, Kay AB, Larche M. Immunoglobulin E-independent major histocompatibility complex-restricted T cell peptide epitope-induced late asthmatic reactions. J Exp Med 1999 189: 1885 94.
5. Bateman EA, Ardern-Jones MR, Ogg GS. Persistent central memory phenotype of circulating Fel d 1 peptide/DRB1*0101 tetramer-binding CD4+ T cells. J Allergy Clin Immunol 2006 118: 1350 6.
6. Berth-Jones J. Six area, six sign atopic dermatitis (SASSAD) severity score: a simple system for monitoring disease activity in atopic dermatitis. Br J Dermatol 1996 135 (Suppl. 48 25 30.
7. Morabito L, Montesinos MC, Schreibman DM et al. Methotrexate and sulfasalazine promote adenosine release by a mechanism that requires ecto-5′-nucleotidase-mediated conversion of adenine nucleotides. J Clin Invest 1998 101: 295 300.
8. Genestier L, Paillot R, Fournel S et al. Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells. J Clin Invest 1998 102: 322 8.
9. Sigmundsdottir H, Johnston A, Gudjonsson JE et al. Methotrexate markedly reduces the expression of vascular E-selectin, cutaneous lymphocyte-associated antigen and the numbers of mononuclear leucocytes in psoriatic skin. Exp Dermatol 2004 13: 426 34.
10. Johnston A, Gudjonsson JE, Sigmundsdottir H et al. The anti-inflammatory action of methotrexate is not mediated by lymphocyte apoptosis, but by the suppression of activation and adhesion molecules. Clin Immunol 2005 114: 154 63.